Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress [Yahoo! Finance]
Amarin Corporation plc - American Depositary Shares (AMRN)
Last amarin corporation plc - american depositary shares earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.amarincorp.com/investors
Company Research
Source: Yahoo! Finance
plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian partner HLS Therapeutics, a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease (CVD), announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress (CCC), taking place in Quebec City, Quebec, Canada from October 23 to 26, 2025. These presentations reflect the continued commitment of Amarin and HLS to advancing the broader therapeutic potential of Icosapent Ethyl (IPE) and Eicosapentaenoic Acid (EPA), further highlighting their dedication to improving cardiovascular care for appropriate patients. Data to be presented at CCC 2025 highlights the clinical value of IPE for cardiometabolic conditions as well as further attempts to explore the mechanistic effects of EPA on atherogenic lipoproteins and in endothelial cells during inflammation when combined with a
Show less
Read more
Impact Snapshot
Event Time:
AMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corporation plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AMRN
News
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk PatientsGlobeNewswire
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025GlobeNewswire
- Amarin (NASDAQ:AMRN) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMRN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
- Amarin Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular BenefitGlobeNewswire
AMRN
Earnings
- 10/29/25 - Beat
AMRN
Sec Filings
- 10/31/25 - Form 3
- 10/29/25 - Form 10-Q
- 10/29/25 - Form 8-K
- AMRN's page on the SEC website